&NA;MDL 100240 is the orally-active prodrug of MDL 100173, the most active inhibitor of ACE and neutral endopeptidase known. It is currently undergoing phase I clinical investigation with Hoechst Marion Roussel in the US for the treatment of hypertension and is in preclinical investigation for use in heart failure.